George Hill joined Deutsche Bank as a Managing Director and equity research analyst covering the Healthcare Technology & Service sector in April 2019. He’s been covering the healthcare technology and pharmaceutical services space for over 20 years. Mr. Hill frequently appears in the media, as a regular speaker at industry events, and lectured at the Wharton School on healthcare technology topics. He was Managing Director and senior equity research analyst at RBC Capital Markets, covered the drug supply chain and healthcare technology industries. Prior to RBC, he held similar positions at Deutsche Bank, Citigroup and SVB Leerink. He spent time as the senior calling officer for Leerink’s healthcare services investment banking group. Mr. Hill started his career in investment research as an investment associate at Citigroup Asset Management. Before that, he was a journalist covered the pharmaceutical marketing and services space. Mr. Hill holds a bachelor’s degree from Rutgers University.
Justin Lake joined Wolfe Research in April 2016 as a Managing Director. He specializes in coverage of Managed care, Hospitals and Small/Mid Cap Healthcare Providers, including Dialysis and Surgical Facilities. Justin was ranked No. 1 in Institutional Investor’s “All-American Research Team” survey in 2022 in the combined Managed Care and Health Care Facilities category. He was dual-ranked No. 1 for both Managed Care and Health Care Facilities in 2013 and 2014 and was ranked No. 2 in the combined category from 2017 through 2021.
Immediately prior to joining Wolfe Research, Justin served as an analyst at Viking Global Investors covering the healthcare sector. Previously, Justin was a Managing Director on the sell side in the healthcare groups at both JPMorgan Chase & Co. and UBS AG. Justin has an MBA from NYU Stern School of Business and is a CFA charter holder.
Whit Mayo is a Senior Managing Director and Senior Research Analyst covering Healthcare Providers & Managed Care at SVB Securities. He leads SVB Securities’ research across payors, providers, and health systems and provides strategic guidance and insight for our clients and partners.
Whit joined the firm in 2021 from UBS, where he most recently served as Managing Director. Prior to that, Whit covered the sector at Baird and Stephens, Inc.
In 2020 he was ranked in Institutional Investor’s All-America Research Team within the Health Care Facilities & Managed Care category.
He earned his Bachelor of Arts in Economics at Sewanee, The University of the South.
David Dill is president and chief executive officer of LifePoint Health. In this role, he is responsible for the development and oversight of LifePoint’s strategic priorities and organizational growth, advancing the company’s mission and strengthening its culture enterprise-wide. He joined LifePoint in 2007 as executive vice president and chief financial officer before serving in his most recent role as president and chief operating officer from 2009 to 2018. Under his leadership, the company has expanded its footprint to 89 hospital campuses, with revenue growing from $3 billion in 2009 to more than $8 billion in 2018, and enhanced its focus on quality and patient safety.
Before joining LifePoint, David was executive vice president of Fresenius Medical Care North America and chief executive officer in the East Division of Fresenius Medical Care Services, a wholly owned subsidiary of Fresenius Medical Care AG & Co. KGaA.
David has served on various governing boards for the American Hospital Association and is currently a member of the board of trustees for the Murray State University Foundation.
Teresa is a tenured executive with a valuable combination of public company and extensive private equity ownership experience. She is comfortable leading complex, multi‐site, multi‐state, large public and private organizations operating in a highly regulated industry.
Teresa serves on the board of a listed company, Harrow Health (NASDAQ: HROW), an ophthalmic pharmaceutical company. She joined the board in March 2020 and serves as the Audit Committee Chair and as a member of the Compensation, Nomination and Corporate Governance Committees. Late 2021, she joined the board of ATI Physical Therapy (NYSE: ATIP) and serves as a Compliance Committee Chair and as a member of the Audit Committee.
In addition, she is currently leveraging her extensive private equity ownership experience serving on multiple PE‐backed corporate boards across multiple sectors, including life sciences, specialty pharmacy, healthcare services, and integrated software solutions. Her experience includes serving as a financial expert in the capacity of Audit Committee Chair or as a member of the Audit Committee.
Throughout her career, she has successfully led two IPOs, a leveraged buy‐out and multiple transformational mergers and acquisitions. Her public company experience incorporates strategy development, risk assessment, investor relations, and corporate governance with active participation and leadership in board, audit committee, compliance, and special committee meetings over the course of her career.
Identifying and executing on value creation opportunities and viable exit strategies are hallmarks of her career. As a senior executive, she focused her passion for leading transformational change through people, processes and technology while building high performing teams and a culture of excellence.
In her role as CFO and EVP at Envision Healthcare, a privately held company with over $8 billion in revenue, Teresa focused on leading transformational change, including modernization of the company’s infrastructure. During a period of leadership transition, she served in an interim role in the Office of the CEO and as Co‐President of the company’s ambulatory surgery center segment (AMSURG) representing over $2 billion in revenue for the company. She established an enterprise‐wide business intelligence and analytics team partnering to deliver useful information to drive critical business decisions. From a technology perspective, she led the company through the selection, design, and initial implementation of a new ERP system.
Serving in an interim role at Brookdale Senior Living (NYSE: BKD), the nation’s largest senior living and retirement community company with revenue exceeding $5 billion. Teresa partnered with the newly appointed CEO to execute a transition strategy, while overseeing the company’s public company reporting requirements.
Prior to this position, Teresa served as CFO and EVP at Surgery Partners (NASDAQ: SGRY), leading the company through an IPO in 2015. The company grew through a combination of multiple transformational mergers and acquisitions, including National Surgical Healthcare in 2017 and Symbion in 2014 with revenue exceeding $2 billion in 2017. During this same period, while integrating operations and realizing cost synergies, the company continued to grow top‐line revenues, with same‐facility growth averaging approximately 10% per year.
As CFO and EVP at Symbion (NASDAQ: SMBI), she joined the company while in the initial startup phase, scaled the infrastructure, deployed growth capital and led the company through an IPO in 2004. She served as a strategic, operational CFO with a focus on tuck‐in acquisitions and organic growth. The company completed a leveraged buy‐out in 2007 during the height of a national financial crisis with Teresa’s leadership critical to the company’s success in light of these broader economic headwinds.
Teresa was appointed to the Securities and Exchange Commission’s Roundtable on Implementation of Internal Control Reporting Provisions in 2005.
She started her career in healthcare in the audit and consulting practice with Deloitte in Nashville, Tennessee. Teresa earned her Bachelor’s degree from Trevecca Nazarene University, graduating with Summa Cum Laude honors and completed the requirements to be a Certified Public Accountant (currently inactive) in the State of Tennessee.